Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 2, 2015, Pages 160-169

  Doherty, Benjamin M ^a,b   Schultz, Stephanie A ^a,b   Oh, Jennifer M ^a,b   Koscik, Rebecca L ^b   Dowling, N Maritza ^b   Barnhart, Todd E ^b   Murali, Dhanabalan ^b   Gallagher, Catherine L ^a,b   Carlsson, Cynthia M ^a,b   Bendlin, Barbara B ^a,b   LaRue, Asenath ^b   Hermann, Bruce P ^b   Rowley, Howard A ^b   Asthana, Sanjay ^a,b   Sager, Mark A ^b   Christian, Brad T ^b   Johnson, Sterling C ^a,b   Okonkwo, Ozioma C ^a,b  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Amyloid; Cognition; Cortical thickness; Preclinical AD

Indexed keywords

EID: 84938686236     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.01.003     Document Type: Article

References (51)

1. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
2. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
3. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
4. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804.
5. Jack C.R., Wiste H.J., Lesnick T.G., Weigand S.D., Knopman D.S., Vemuri P., et al. Brain beta-amyloid load approaches a plateau. Neurology 2013, 80:890-896.
6. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12:357-367.
7. Dickerson B.C., Bakkour A., Salat D.H., Feczko E., Pacheco J., Greve D.N., et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009, 19:497-510.
8. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
9. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9:195-207.
10. Becker J.A., Hedden T., Carmasin J., Maye J., Rentz D.M., Putcha D., et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011, 69:1032-1042.
11. Dore V., Villemagne V.L., Bourgeat P., Fripp J., Acosta O., Chetelat G., et al. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 2013, 70:903-911.
12. Fortea J., Sala-Llonch R., Bartres-Faz D., Llado A., Sole-Padulles C., Bosch B., et al. Cognitively preserved subjects with transitional cerebrospinal fluid ss-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biol Psychiatry 2011, 70:183-190.
13. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008, 65:1509-1517.
14. Wirth M., Madison C.M., Rabinovici G.D., Oh H., Landau S.M., Jagust W.J. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci 2013, 33:5553-5563.
15. Marchant N.L., Reed B.R., Sanossian N., Madison C.M., Kriger S., Dhada R., et al. The aging brain and cognition: contribution of vascular injury and abeta to mild cognitive dysfunction. JAMA Neurol 2013, 70:488-495.
16. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., et al. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
17. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
18. Sager M.A., Hermann B., La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J Geriatr Psychiatry Neurol 2005, 18:245-249.
19. Johnson S.C., Christian B.T., Okonkwo O.C., Oh J.M., Harding S., Xu G., et al. Amyloid burden and neural function in people at risk for Alzheimer's disease. Neurobiol Aging 2014, 35:576-584.
20. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005, 25:7709-7717.
21. Dowling N.M., Hermann B., La Rue A., Sager M.A. Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease. Neuropsychology 2010, 24:742-756.
22. Koscik R.L., La Rue A., Jonaitis E., Okonkwo O.C., Johnson S.C., Bendlin B.B., et al. Emergence of mild cognitive impairment in late-middle-aged adults in the Wisconsin Registry for Alzheimer's Prevention. Dement Geriatr Cogn Disord 2014, 38:16-30.
23. Schmidt M. Rey auditory verbal learning test: a handbook 1996, Western Psychological Services, Torrance, CA.
24. Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale 1997, Psychological Corporation, San Antonio, TX.
25. Trenerry M.R., Crosson B., DeBoe J., Leber W.R. Stroop neuropsychological screening test manual 1989, Psychological Assessment Resources, Odessa, FL.
26. Reitan R.M., Wolfson D. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation 1985, Neuropsychology Press, Tucson, AZ.
27. Wechsler D. Wechsler Abbreviated Scale of Intelligence 1999, Psychological Corporation, San Antonio, TX.
28. Benton A.L. Neuropsychological assessment. Annu Rev Psychol 1994, 45:1-23.
29. Kaplan E.F., Goodglass H., Weintraub S. The Boston Naming Test 1983, Lea & Febiger, Philadelphia, PA. 2nd ed.
30. Wilkinson G.S. Wide Range Achievement Test Administration Manual 1993, Wide Range Incorporated, Wilmington, DE.
31. Whitwell J.L., Tosakulwong N., Weigand S.D., Senjem M.L., Lowe V.J., Gunter J.L., et al. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. Neuroimage Clin 2013, 2:249-257.
32. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
33. Killiany R.J., Gomez-Isla T., Moss M., Kikinis R., Sandor T., Jolesz F., et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000, 47:430-439.
34. Dickerson B.C., Goncharova I., Sullivan M.P., Forchetti C., Wilson R.S., Bennett D.A., et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging 2001, 22:747-754.
35. Killiany R.J., Hyman B.T., Gomez-Isla T., Moss M.B., Kikinis R., Jolesz F., et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002, 58:1188-1196.
36. Poulin S.P., Dautoff R., Morris J.C., Barrett L.F., Dickerson B.C. Alzheimer's Disease Neuroimaging I. Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Res 2011, 194:7-13.
37. Lehericy S., Baulac M., Chiras J., Pierot L., Martin N., Pillon B., et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. AJNR Am J Neuroradiol 1994, 15:929-937.
38. Mizuno K., Wakai M., Takeda A., Sobue G. Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: an MRI volumetric and memory assessment study. J Neurol Sci 2000, 173:18-24.
39. Basso M., Yang J., Warren L., MacAvoy M.G., Varma P., Bronen R.A., et al. Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease. Psychiatry Res 2006, 146:251-261.
40. Farrow T.F., Thiyagesh S.N., Wilkinson I.D., Parks R.W., Ingram L., Woodruff P.W. Fronto-temporal-lobe atrophy in early-stage Alzheimer's disease identified using an improved detection methodology. Psychiatry Res 2007, 155:11-19.
41. Cavedo E., Boccardi M., Ganzola R., Canu E., Beltramello A., Caltagirone C., et al. Local amygdala structural differences with 3T MRI in patients with Alzheimer disease. Neurology 2011, 76:727-733.
42. Striepens N., Scheef L., Wind A., Popp J., Spottke A., Cooper-Mahkorn D., et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord 2010, 29:75-81.
43. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995, 16:271-278. discussion 78-84.
44. Garcia Gil M.L., Moran M.A., Gomez-Ramos P. Ubiquitinated granular structures and initial neurofibrillary changes in the human brain. J Neurol Sci 2001, 192:27-34.
45. Duyckaerts C., Colle M.A., Dessi F., Piette F., Hauw J.J. Progression of Alzheimer histopathological changes. Acta Neurol Belg 1998, 98:180-185.
46. Bancher C., Jellinger K.A. Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects. Acta Neuropathol 1994, 88:565-570.
47. Chetelat G., La Joie R., Villain N., Perrotin A., de La Sayette V., Eustache F., et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin 2013, 2:356-365.
48. Hampel H. Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. J Alzheimers Dis 2013, 33:S79-S86.
49. Hedden T., Oh H., Younger A.P., Patel T.A. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 2013, 80:1341-1348.
50. Salthouse T.A. Aging and measures of processing speed. Biol Psychol 2000, 54:35-54.
51. Morey R.A., Petty C.M., Xu Y., Hayes J.P., Wagner H.R., Lewis D.V., et al. A comparison of automated segmentation and manual tracing for quantifying hippocampal and amygdala volumes. Neuroimage 2009, 45:855-866.